SCHEMBL6608224

SCHEMBL6608224

COCCN(CCOC)Cc1oc(Nc2c(C)cc(C)cc2C)nc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 16/20 0.46
RAPGEF4 Q8WZA2 2/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
DUSP3 P51452 1/20 0.32
PTPN11 Q06124 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606837 0.95 CRHR1 (0.46) CRHR1DUSP3PTPN11KMT2A
SCHEMBL6609376 0.93 CRHR1 (0.52) CRHR1
SCHEMBL6607781 0.88 CRHR1 (0.51) CRHR1
SCHEMBL6607067 0.88 CRHR1 (0.58) CRHR1
SCHEMBL6605658 0.84 CRHR1 (0.65) CRHR1
SCHEMBL6608553 0.81 CRHR1 (0.64) CRHR1
SCHEMBL6607106 0.79 CRHR1 (0.65) CRHR1
SCHEMBL6611522 0.78 CRHR1 (0.64) CRHR1
SCHEMBL6607977 0.74 CRHR1 (0.64) CRHR1
SCHEMBL6607776 0.72 CRHR1 (0.67) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320365-A4 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL MYERS SQUIBB CO (US) 2004-03-17 EP claimed
EP-1320365-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR Bristol-Myers Squibb Company (US) 2003-06-25 EP claimed
US-6515005-B2 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders BRISTOL-MYERS SQUIBB COMPANY 2003-02-04 US claimed
US-20020161019-A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor BRISTOL-MYERS SQUIBB COMPANY 2002-10-31 US claimed
WO-2002024200-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-28 WO claimed
EP-1320365-A4 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL MYERS SQUIBB CO (US) 2004-03-17 EP disclosed
EP-1320365-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR Bristol-Myers Squibb Company (US) 2003-06-25 EP disclosed
US-6515005-B2 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders BRISTOL-MYERS SQUIBB COMPANY 2003-02-04 US disclosed
US-20020161019-A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor BRISTOL-MYERS SQUIBB COMPANY 2002-10-31 US disclosed
WO-2002024200-A1 SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161019-A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor CRH, CRHR1, CRHR2 CRHR1 2/4885RAPGEF4 2356/4885ALDH1A1 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.